We are applying our drug developing expertise to design novel anti-cancer medicines that address serious unmet medical needs in oncology and autoimmune disease. Our team of experts is capable of creating mAbs, multi-specific antibodies and ADCs against targets of interest and providing phase I-ready assets to partners.
Our three unique assets targeting oxMIF, the key to drugging MIF:
ON203: OncoOne’s optimized mAb targeting oxMIF in solid tumors
ON104: OncoOne’s oxMIF mAb specifically formulated for autoimmune disorders and severe inflammatory conditions
ON-05: the first asset from OncoOne’s proprietary PreTarg-it™ platform combining the tumor aggregation of oxMIF and radiotherapy in a powerful, yet highly targeted radioimmunoconjugate therapy
OncoOne is actively seeking partnerships, collaborations, and Series B investors in 2022 to accelerate the progression of our oxMIF candidates to the clinic
To discuss partnering or collaboration opportunities, please contact OncoOne’s Chief Business Officer, Brent Meadows.